Vividion Therapeutics’ $135 Million Series C Financing

Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics, Inc. and the lead investors on the deal.

Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced the completion of a $135 million Series C financing. 

The financing was co-led by new investors Logos Capital and Boxer Capital of Tavistock Group, with participation from additional new investors SoftBank Investment Advisers, Avoro Capital Advisors, funds and accounts managed by BlackRock, RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital (a Citadel company), Woodline Partners LP, Acuta Capital, and Driehaus Capital. Existing investors ARCH Venture Partners, BVF Partners L.P., Casdin Capital, Mubadala Capital, Nextech Invest, and Versant Ventures also participated in the round.

Vividion has integrated multiple emerging technologies into its platform that enable the company to discover and develop potential therapies for well-known but previously undruggable targets. The platform conveys the unique ability to: find unknown or cryptic functional pockets on high-value targets; interact with those pockets using its first-in-kind, proteome-trained covalent chemistry library; and ensure precise selectivity across the entire proteome with its industrial-scale chemoproteomics capabilities. Leveraging this platform, Vividion is advancing a pipeline of potent and selective small molecule therapies across a range of oncology and immunology indications.

The Wilson Sonsini team that advised Vividion on patent matters related to the financing includes partner Mike Hostetler (Picture), counsel Uale Taotafa, and patent agents Katrina Otrubova, and August Renshaw.

The Wilson Sonsini team advising Logos Capital and Boxer Capital as lead investors on the financing includes partner Dan Koeppen, associate Meghan Burton, and venture counsel attorneys Bridget Balisy and Brandon Shaw.

Involved fees earner: Bridget Balisy – Wilson Sonsini Goodrich & Rosati; Meghan Burton – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Dan Koeppen – Wilson Sonsini Goodrich & Rosati; Katrina Otrubova – Wilson Sonsini Goodrich & Rosati; August Renshaw – Wilson Sonsini Goodrich & Rosati; Brandon Shaw – Wilson Sonsini Goodrich & Rosati; Uale Taotafa – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Boxer Capital; Logos Capital; Vividion Therapeutics;

Author: Martina Bellini